<DOC>
	<DOCNO>NCT01768702</DOCNO>
	<brief_summary>Evaluation safety efficacy C3BS-CQR-1 compare overall response standard care C3BS-CQR-1 relative standard care sham procedure .</brief_summary>
	<brief_title>Safety Efficacy Autologous Cardiopoietic Cells Treatment Ischemic Heart Failure .</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Eligible patient must meet follow inclusion criterion : 1 . Age ≥ 18 &lt; 80 year . 2 . Systolic dysfunction leave ventricular ejection fraction ( LVEF ) ≤ 35 % assessed echocardiography . 3 . Ischemic heart failure without know need revascularization . 4 . Total MLHFQ score &gt; 30 . 5 . Ability perform 6 minute walk test &gt; 100 ≤ 400 m. 6 . History hospitalization heart failure ( HF ) within 12 month prior screen treatment outpatient clinic intravenous vasoactive therapy ( include vasodilator , positive inotropic agent vasopressor ) diuretic worsen Heart Failure within 12 month prior screen . 7 . Be must within previous 12 month New York Heart Association ( NYHA ) Class III IV Interagency Registry Mechanically Assisted Circulatory Support ( INTERMACS ) class 4 , 5 , 6 7 , time inclusion , must least NYHA Class II great . 8 . Use ACE inhibitor and/or angiotensin receptor blocker ( ARB ) ; beta blocker , least 3 month prior screen visit , unless intolerant contraindicate . 9 . Stable dose ACE inhibitor , angiotensin receptor blocker , beta blocker , aldosterone blocker , diuretic least one month prior screen visit , define ≤50 % change total dose agent . 10 . Willing able give write informed consent . Exclusion Criteria ( summarize ) : Eligible patient must meet none follow exclusion criterion : 1 . Women pregnant , confirm positive urine serum human chorionic gonadotropin laboratory test screening . 2 . Women childbearing potential without negative serum urine pregnancy test screening . Women postmenopausal ( 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum FSH level &gt; 40 mIU/mL 6 week post surgical bilateral oophorectomy ) surgically sterile consider childbearing potential . Reliable contraception include surgical sterilization , hormonal contraception , doublebarrier method . 3 . Men refuse exercise reliable form contraception . 4 . Myocardial infarction , unstable angina percutaneous coronary intervention ( PCI ) within 90 day prior screen , coronary artery bypass graft surgery within 180 day prior screen . 5 . Patient cardiac transplant list previously receive solid organ transplant . 6 . Previously underwent cardiac surgery remodel procedure , leave ventricular assist device placement cardiomyoplasty . This exclusion apply patient underwent ventricularplasty without placement device one year ago . 7 . Patient undergone cardiac resynchronization therapy within 6 month prior screen . 8 . Severe uncontrolled HF require need intensive intravenous diuretic inotropic support within 1 month prior screen . 9 . Inability perform 6 minute walk test due physical limitation HF include : 1 . Severe peripheral vascular disease 2 . Severe pulmonary disease chronic obstructive pulmonary disease limit exercise 3 . Orthopedic limitation , severe muscular disease , joint muscular disease neurological disorder ( old stroke neuropathy ) limit ability walk 6 minute . 10 . Dependence chronic oral steroid therapy . 11 . Stroke transient ischemic attack lead limitation low extremity occur within 180 day prior screen . 12 . Active myocarditis , constrictive pericarditis , restrictive , hypertrophic congenital cardiomyopathy . 13 . BMI &lt; 19 &gt; 45 . 14 . Left ventricular thrombus . 15 . Left ventricular ( LV ) wall thickness &lt; 8mm visualized 50 % LV , define `` LV nogo zone '' . 16 . LV aneurysm candidate surgical aneurysmectomy . 17 . Sustained ventricular tachycardia ventricular fibrillation lead automatic implantable cardioverter/defibrillator ( AICD ) therapy ( shock ) within 3 month prior screen . 18 . Primary significant organic valvular heart disease . 19 . Moderate severe aortic valve disease preclude catheter entry LV . 20 . Mechanical prosthetic valve aortic mitral position . 21 . Chronic infection active malignancy . 22 . Patient compromise renal function reflect serum creatinine level &gt; 3.0 mg/dL ( &gt; 0.265 mmol/L ) currently dialysis . 23 . Hematocrit &lt; 28 % . 24 . Atherosclerosis and/or tortuosity aorta , iliac femoral artery degree could impede preclude safe retrograde passage delivery catheter . 25 . Chronic immunosuppressive therapy due inflammatory systemic disease . 26 . Patient test positive HIV 1 2 , Hepatitis B C , human Tcell lymphotrophic virus ( HTLV ) 1 2 ( required regulation ) syphilis . 27 . Exposure previous experimental cell angiogenic therapy and/or myocardial laser therapy and/or therapy another investigational drug within 60 day prior screen enrollment concurrent study may confound result study . 28 . Known drug alcohol dependence factor interfere study conduct interpretation result opinion investigator suitable participate . 29 . Any illness congestive heart failure might reduce life expectancy le 2 year screen . 30 . Known relevant allergy and/or hypersensitivity Dextran plasma volume expanders include Gentran , Hyskon Macrodex .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Chronic Heart Failure Ischemic Origin</keyword>
</DOC>